Obstacles to Early Diagnosis and Treatment of Inherited von Willebrand Disease: Current Perspectives

References

• De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood. 2009;113:5049–5057. doi:10.1182/blood-2008-10-165621
   PubMed Web of Science ®Google Scholar
• Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost. 2014;40:17–27. doi:10.1055/s-0033-1363155
   PubMed Web of Science ®Google Scholar
• De Jong A, Eikenboom J. Developments in the diagnostic procedures for von Willebrand disease. J Thromb Haemost. 2016;14:449–460. doi:10.1111/jth.13243
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69:454–459. doi:10.1182/blood.V69.2.454.454
   PubMed Web of Science ®Google Scholar
• Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395–424. doi:10.1146/annurev.biochem.67.1.395
   PubMed Web of Science ®Google Scholar
• Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem. 1983;258:2065–2067. doi:10.1016/S0021-9258(18)32879-5
   PubMed Web of Science ®Google Scholar
• Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest. 1985;76:1102–1106. doi:10.1172/JCI112064
   PubMed Web of Science ®Google Scholar
• Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem. 1989;264:19514–19527. doi:10.1016/S0021-9258(19)47144-5
   PubMed Web of Science ®Google Scholar
• Mancuso DJ, Tuley EA, Westfield LA, et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry. 1991;30:253–269. doi:10.1021/bi00215a036
   PubMed Web of Science ®Google Scholar
• Zhou YF, Eng ET, Zhu J, et al. Sequence and structure relationships within von Willebrand factor. Blood. 2012;120:449–458. doi:10.1182/blood-2012-01-405134
   PubMed Web of Science ®Google Scholar
• Haberichter SL. Biosynthesis and organization of von Willebrand factor. In: Federici AB, Lee CA, Berntorp EE, editors. Von Willebrand Disease: Basic and Clinical Aspects. Oxford: Wiley-Blackwell; 2011:7–29.
   Google Scholar
• Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost. 2005;3:1710–1716. doi:10.1111/j.1538-7836.2005.01360.x
   PubMed Web of Science ®Google Scholar
• Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program. 2009;2009:106–112. doi:10.1182/asheducation-2009.1.106
   Google Scholar
• Castaman G, Goodeve A, Eikenboom JC; on behalf of the European Group on von Willebrand disease (EUVWD). Principles of care for diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98:667–674. doi:10.3324/haematol.2012.077263
   PubMed Web of Science ®Google Scholar
• Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103–2114. doi:10.1111/j.1538-7836.2006.02146.x
   PubMed Web of Science ®Google Scholar
• Hampshire DJ, Goodeve AC. The International Society on Thrombosis and Haemostasis von Willebrand disease database: an update. Semin Thromb Hemost. 2011;37:470–479. doi:10.1055/s-0031-1281031
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost. 2011;37:425–426. doi:10.1055/s-0031-1280567
   Web of Science ®Google Scholar
• Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood. 2009;114(6):1158–1165. doi:10.1182/blood-2009-01-153296
   PubMed Web of Science ®Google Scholar
• Leissinger C, Carcao M, Gill JC, Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia. 2014;20(2):158–167. doi:10.1111/hae.12254
   PubMed Web of Science ®Google Scholar
• Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and the phenotype in type 1 von Willebrand disease (VWD): results from the European study MCMDM-1 VWD. Blood. 2008;111:3531–3539. doi:10.1182/blood-2007-08-109231
   PubMed Web of Science ®Google Scholar
• Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113(3):526–534. doi:10.1182/blood-2008-04-152280
   PubMed Web of Science ®Google Scholar
• Mannucci PM. New therapies for von Willebrand disease. Hematology Am Soc Hematol Educ Program. 2019;2019:590–595. doi:10.1182/hematology.2019000368
   Google Scholar
• Batlle J, Lopez-Fernandez MF, Fraga EL, et al. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis. 2009;20:89–100. doi:10.1097/MBC.0b013e3283254570
   PubMed Web of Science ®Google Scholar
• Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171–232. doi:10.1111/j.1365-2516.2007.01643.x
   PubMed Web of Science ®Google Scholar
• Laffan MA, Lester W, O’Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014;167(4):453–465. doi:10.1111/bjh.13064
   PubMed Web of Science ®Google Scholar
• Franchini M. Surgical prophylaxis in von Willebrand’s disease: a difficult balance to manage. Blood Transfus. 2008;6(Suppl 2):33–38.
   Google Scholar
• O’Donnell JS, Lavin M. Perioperative management of patients with von Willebrand disease. Hematology Am Soc Hematol Educ Program. 2019;2019:604–609. doi:10.1182/hematology.2019000065
   Google Scholar
• Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Pannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia. 2012;18(3):e173–e187. doi:10.1111/j.1365-2516.2012.02758.x
   PubMed Web of Science ®Google Scholar
• Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low FVIII content treated with three virus-inactivation/removal methods. J Thromb Haemost. 2005;3(10):2219–2227. doi:10.1111/j.1538-7836.2005.01435.x
   PubMed Web of Science ®Google Scholar
• Turecek PL, Mitterer A, Matthiessen HP, et al. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie. 2009;29(Suppl 1):S32–S38. doi:10.1055/s-0037-1617202
   PubMed Web of Science ®Google Scholar
• Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis. 2014;25:206–216. doi:10.1097/MBC.0000000000000065
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Kempton C, Millar C, et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective trial. Blood. 2013;122(5):648–657. doi:10.1182/blood-2013-01-479527
   PubMed Web of Science ®Google Scholar
• Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038–2046. doi:10.1182/blood-2015-02-629873
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mamaev A, Wang JD, et al. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. J Thromb Haemost. 2019;17(1):52–62. doi:10.1111/jth.14313
   PubMed Web of Science ®Google Scholar
• Albanez S, Ogiwara K, Michels A, et al. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. J Thromb Haemost. 2016;14:953–963. doi:10.1111/jth.13294
   PubMed Web of Science ®Google Scholar
• Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in 0 blood group subjects explains how AB0 determinants influence plasma von Willebrand factor. Blood. 2008;111:3540–3545. doi:10.1182/blood-2007-11-122945
   PubMed Web of Science ®Google Scholar
• Bowen DJ. An influence of AB0 group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost. 2003;1:33–40. doi:10.1046/j.1538-7836.2003.00007.x
   PubMed Web of Science ®Google Scholar
• Sadler JE. Slippery criteria for von Willebrand disease type 1. J Thromb Haemost. 2004;2:1720–1723. doi:10.1111/j.1538-7836.2004.00933.x
   PubMed Web of Science ®Google Scholar
• Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4:766–773. doi:10.1111/j.1538-7836.2006.01847.x
   PubMed Web of Science ®Google Scholar
• Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease(MCMDM-1VWD). Blood. 2007;109:112–121. doi:10.1182/blood-2006-05-020784
   PubMed Web of Science ®Google Scholar
• Flood VH, Christopherson PA, Gill JC, et al. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood. 2016;127:2481–2488. doi:10.1182/blood-2015-10-673681
   PubMed Web of Science ®Google Scholar
• Lavin M, Aguila S, Schneppenheim S, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017;130:2344–2353. doi:10.1182/blood-2017-05-786699
   PubMed Web of Science ®Google Scholar
• Lavin M, O’Donnell JS. How I treat low von Willebrand factor levels. Blood. 2019;133:795–804. doi:10.1182/blood-2018-10-844936
   PubMed Web of Science ®Google Scholar
• Rydz N, James PD. The evolution and value of bleeding assessment tools: the evolution and value of bleeding assessment tools. J Thromb Haemost. 2012;10:2223–2229. doi:10.1111/j.1538-7836.2012.04923.x
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders: ISTH/SSC bleeding assessment tool. J Thromb Haemost. 2010;8:2063–2065. doi:10.1111/j.1538-7836.2010.03975.x
   PubMed Web of Science ®Google Scholar
• Spradbrow J, Letourneau S, Grabell J, et al. Bleeding assessment tools to predict von Willebrand disease: utility of individual bleeding symptoms. Res Pract Thromb Haemost. 2020;4:92–99. doi:10.1002/rth2.12256
   Web of Science ®Google Scholar
• Favaloro EJ. The Platelet Function Analyser (PFA)-100 and von Willebrand disease: a story well over 16 years in the making. Haemophilia. 2015;21:642–645. doi:10.1111/hae.12710
   PubMed Web of Science ®Google Scholar
• Sharma R, Haberichter SL. New advances in the diagnosis of von Willebrand disease. Hematology Am Soc Hematol Educ Program. 2019;2019:596–600. doi:10.1182/hematology.2019000064
   Google Scholar
• Castaman G, Tosetto A, Cappelletti A, et al. Validation of a rapid test (VWF-LIA) for the quantitative determination of the von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thromb Res. 2010;126:227–231. doi:10.1016/j.thromres.2010.06.013
   PubMed Web of Science ®Google Scholar
• Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Haemost. 2006;32:485–491. doi:10.1055/s-2006-947862
   PubMed Web of Science ®Google Scholar
• Vanhoorelke K, Cauwenberghs N, Vauterin S, et al. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost. 2000;83:107–113. doi:10.1055/s-0037-1613765
   PubMed Web of Science ®Google Scholar
• Flood VH, Gill JC, Morateck PA, et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010;116:280–286. doi:10.1182/blood-2009-10-249102
   PubMed Web of Science ®Google Scholar
• Verfaillie CJ, De Witte E, Devreese KM. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease. Int J Lab Hematol. 2013;35:555–565. doi:10.1111/ijlh.12087
   PubMed Web of Science ®Google Scholar
• Flood VH, Abshire TC, Christopherson PA, et al. Von Willebrand disease in the United States: perspective from the Zimmerman program. Ann Blood. 2018;3:7. doi:10.21037/aob.2017.12.05
   Google Scholar
• Bodò I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J. von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(7):1345–1350. doi:10.1111/jth.12964
   PubMed Web of Science ®Google Scholar
• Boender J, Eikenboom J, van der Bom JC, et al. Clinically relevant differences between assays for von Willebrand factor activity. J Thromb Haemost. 2018;16(12):2413–2424.
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of FVIII/von Willebrand factor in plasma and platelets. J Clin Invest. 1980;65:1318–1325. doi:10.1172/JCI109795
   PubMed Web of Science ®Google Scholar
• Bowyer AE, Goodfellow KJ, Seidel H, et al. Evaluation of a semiautomated von Willebrand factor multimer assay, the hydragel von Willebrand multimer, by two European Centers. Res Pract Thromb Haemost. 2018;2:790–799. doi:10.1002/rth2.12141
   PubMed Web of Science ®Google Scholar
• Castaman G, Linari S. Advances in diagnosis of von Willebrand disease. Exp Opin Orphan Drugs. 2019;7:147–155. doi:10.1080/21678707.2019.1609352
   Web of Science ®Google Scholar
• Favaloro EJ, Grispo L, Exner T, et al. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and II, von Willebrand’s disease. Blood Coagul Fibrinolysis. 1991;2:285–291. doi:10.1097/00001721-199104000-00011
   PubMed Web of Science ®Google Scholar
• Jousselme E, Jourdy Y, Rugeri L, et al. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF. Int J Lab Hematol. 2018;40:77–83. doi:10.1111/ijlh.12743
   PubMed Web of Science ®Google Scholar
• Keesler DA, Flood VH. Current issues in diagnosis and treatment of von Willebrand disease. Res Pract Thromb Haemost. 2018;2:34–41. doi:10.1002/rth2.12064
   PubMed Web of Science ®Google Scholar
• Flood VH, Gill JC, Christopherson PA, et al. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost. 2012;10:1417–1424. doi:10.1111/j.1538-7836.2012.04746.x
   PubMed Web of Science ®Google Scholar
• Nishino M, Girma JP, Rothschild C, et al. New variant of von Willebrand disease with defective binding to factor VIII. Blood. 1989;74:1591–1599. doi:10.1182/blood.V74.5.1591.1591
   PubMed Web of Science ®Google Scholar
• Haberichter SL, Balistreri M, Christopherson R, et al. Assay of the von Willlebrand factor (VWF) propeptide to identify type 1 von Willebrand disease patients with decreased VWF survival. Blood. 2006;108:3344–3351. doi:10.1182/blood-2006-04-015065
   PubMed Web of Science ®Google Scholar
• Bellissimo DB, Christopherson PA, Flood VH, et al. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 2012;119:2135–2140. doi:10.1182/blood-2011-10-384610
   PubMed Web of Science ®Google Scholar
• Sharma R, Flood VH. Advances in the diagnosis and treatment of von Willebrand disease. Hematology Am Soc Hematol Educ Program. 2017;2017(1):379–384. doi:10.1182/asheducation-2017.1.379
   PubMed Web of Science ®Google Scholar
• James PD, Notley C, Hegardon C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood. 2007;109:145–154. doi:10.1182/blood-2006-05-021105
   PubMed Web of Science ®Google Scholar
• Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev. 2010;24:123–134. doi:10.1016/j.blre.2010.03.003
   PubMed Web of Science ®Google Scholar
• Christopherson PA, Perry CL, Bellissimo DB, et al. Genotype-phenotype relationship and the role of alloantibodies in type 3 VWD in the Zimmerman Program. Blood. 2017;130(suppl 1):19.
   Google Scholar
• Boender J, Eikenboom J, van der Bom JG, et al. Clinically relevant differences between assays for von Willebrand factor activity. J Thromb Haemost. 2018;16:2413–2424.
   PubMed Web of Science ®Google Scholar
• Castaman G. How I treat von Willebrand disease. Thromb Res. 2020;196:618–625. doi:10.1016/j.thromres.2020.07.051
   PubMed Web of Science ®Google Scholar